BlossomHill Therapeutics (BLSM) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.29
- Estimate
- -$0.90
- Surprise
- -43.6%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
BlossomHill Therapeutics (BLSM) reported a wider loss than forecast — adjusted EPS of -$1.29 against the -$0.90 estimate (a 43.6% shortfall).
Coverage in the report window
- BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights — fiscal.ai, 2026-11-12
- BlossomHill Therapeutics Q3 EPS $(1.29) Misses $(0.93) Estimate — benzinga, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLSM Sell at 5.5/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -43.6% surprise compares with a -540.0% four-quarter average. Next scheduled report: 2027-03-08.
What argues against it
- Quality below floor (2.9 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -201.0%), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.59
- Price target
- $30.80
- Stop
- $13.57
- Upside to target
- +111.1%
- Reward-to-risk
- 7.4:1
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
BLSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $463.7M
- P/E (fwd)
- -3.7
- 52-week range
- $11.02–$27.99
- Off 52-week high
- 47.9%
- RSI (14)
- 47
- Volume vs avg
- 1.49×
- Score today
- 5.5/10